MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase

Phase 3
Completed
Conditions
Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2009-01-09
Last Posted Date
2017-04-21
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
650
Registration Number
NCT00819351
Locations
🇸🇪

Department of Pediatrics, Drottning Sylvias Pediatric Hospital, Gothenburg, Sweden

🇮🇸

University Hospital Reykjavik, Iceland, Reykjavik, Iceland

🇳🇴

Trondheim University Hospital, Trondheim, Norway

and more 3 locations

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

Phase 4
Completed
Conditions
Constipation
Interventions
Other: Placebo, maltodextrin 500 powder for solution
First Posted Date
2008-10-10
Last Posted Date
2018-10-02
Lead Sponsor
Bayer
Target Recruit Count
203
Registration Number
NCT00770432

Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome

Early Phase 1
Completed
Conditions
Constipation
Interventions
Drug: Placebos
First Posted Date
2008-10-03
Last Posted Date
2021-01-15
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
138
Registration Number
NCT00765557

Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia

Phase 1
Conditions
Anti-Biotic Resistance
Klebsiella Pneumoniae
Interventions
Dietary Supplement: VSL#3
First Posted Date
2008-07-25
Last Posted Date
2008-07-25
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
60
Registration Number
NCT00722410
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination

Phase 4
Completed
Conditions
Endoscopy
Interventions
Drug: Clear fluids
Drug: Picosalax
First Posted Date
2008-05-15
Last Posted Date
2015-09-25
Lead Sponsor
Queen's University
Target Recruit Count
198
Registration Number
NCT00677794
Locations
🇨🇦

Hotel Dieu Hospital, Kingston, Ontario, Canada

Comparison of Two Methods of Administration of a PEG Solution

Phase 4
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2008-02-29
Last Posted Date
2016-04-13
Lead Sponsor
Rabin Medical Center
Target Recruit Count
400
Registration Number
NCT00626054
Locations
🇮🇱

Rabin Medical Center, Petach Tikva, Israel

Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV

Phase 4
Conditions
Chronic Hepatitis C
Co-Infection HIV-HCV
Interventions
First Posted Date
2008-02-11
Last Posted Date
2008-02-11
Lead Sponsor
University of Valencia
Target Recruit Count
59
Registration Number
NCT00611819
Locations
🇪🇸

Hospital de Elche, Elche, Alicante, Spain

🇪🇸

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospital Xeral-Cíes, Vigo, Pontevedra, Spain

and more 15 locations

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation

Phase 4
Completed
Conditions
Constipation
Interventions
Drug: Polyethylene glycol 4000 with electrolytes
First Posted Date
2008-01-29
Last Posted Date
2008-10-07
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
67
Registration Number
NCT00603681
Locations
🇫🇮

Tampereen sotainvalidien Veljeskoti, Tampere, Finland

🇫🇮

Vire Koti Kaukaharju assisted-living facility, Tampere, Finland

🇫🇮

Taatala assested-living facility, Tampere, Finland

and more 7 locations

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

Phase 4
Completed
Conditions
Constipation
Interventions
First Posted Date
2007-12-31
Last Posted Date
2009-09-28
Lead Sponsor
Braintree Laboratories
Target Recruit Count
20
Registration Number
NCT00583609

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Not Applicable
Completed
Conditions
Non-Hodgkins Lymphoma
Interventions
Drug: CHOP/Rituximab
First Posted Date
2007-12-17
Last Posted Date
2023-09-14
Lead Sponsor
University of Nebraska
Target Recruit Count
27
Registration Number
NCT00574730
Locations
🇺🇸

Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath